设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2019 年第 6 期 第 14 卷

空腹血糖与急性心肌梗死患者经皮冠状动脉介入术后非罪犯血管病变进展的相关性研究

Relation between fasting blood glucose and nonculprit vessel lesion progression after percutaneous coronary intervention in patients with acute myocardial infarction

作者:王雪杰王健柳景华何松原田佳瑜朱勇

英文作者:

单位:100029首都医科大学附属北京安贞医院心内科二十八病房(王雪杰、王健、柳景华、何松原、田佳瑜),心内十二病房(朱勇)

英文单位:

关键词:急性心肌梗死;空腹血糖;非罪犯血管病变

英文关键词:

  • 摘要:
  • 【摘要】目的    探讨空腹血糖与急性心肌梗死(AMI)患者经皮冠状动脉介入(PCI)术后非罪犯血管病变(NCL)进展的相关性。方法    收集2016年1月至2017年12月于首都医科大学附属北京安贞医院诊断AMI并于2018年6月前于本院再次住院复查冠状动脉造影的192例患者的临床资料。根据随访的冠状动脉造影情况,将患者分为NCL进展组(82例)及NCL无进展组(110例)。比较2组一般资料,并分析空腹血糖与NCL进展的相关性。结果    NCL进展组体重指数、血肌酐、空腹血糖、糖化血清白蛋白、糖化血红蛋白、同型半胱氨酸水平明显高于NCL无进展组,差异均有统计学意义(均P<0.05)。空腹血糖水平(比值比=1.274,95%置信区间:1.077~1.505,P=0.005)及血肌酐水平(比值比=1.020,95%置信区间:1.002~1.038,P=0.027)可独立预测AMI患者PCI术后NCL的进展。空腹血糖与NCL进展呈正相关(r=0.231, P=0.001)。以空腹血糖为5.715 mmol/L为界值预测NCL进展最佳,其敏感度和特异度分别为74.4%及46.4%。结论    在临床工作中空腹血糖预测NCL进展对AMI患者PCI术后危险分层及预后具有一定指导意义,PCI术后患者应定期复查危险因素相关指标,根据具体情况控制达标,以延缓NCL的进展并改善预后及生存质量。

  • 【Abstract】Objective    To analyze the relation between fasting blood glucose and nonculprit vessel lesion(NCL) progression after percutaneous coronary intervention(PCI) in patients with acute myocardial infarction(AMI). Methods    Clinical data of 192 patients who were diagnosed of AMI from January 2016 to December 2017 and had reexamination of coronary angiography before June 2018 in Beijing Anzhen Hospital, Capital Medical University were analyzed. They were divided into NCL progression group(82 cases) and NCL progression-free group(110 cases). Basic information and the correlation between fasting blood glucose and NCL progression were analyzed. Results    Levels of body mass index, serum creatinine, fasting blood glucose, glycated serum albumin, glycated hemoglobin and homocysteine in NCL progression group were significantly higher than those in NCL progression-free group(all P<0.05). Logistic regression showed that fasting blood glucose(odds ratio=1.274, 95% confidence interval: 1.077-1.505, P=0.005) and serum creatinine(odds ratio=1.020, 95% confidence interval: 1.002-1.038, P=0.027) were independent predictors of NCL progression. Partial correlation analysis showed that fasting blood glucose was positively correlated with NCL progression(r=0.231, P=0.001). Receiver operating characteristic curve showed that the boundary point of fasting blood glucose to predict NCL progression was 5.715 mmol/L; the sensitivity was 74.4% and the specificity was 46.4%. Conclusion    Fasting blood glucose is valuable in the prediction of NCL progression and risk stratification after PCI in patients with AMI.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭